ConductScience.org, home

Paper39701285

Management Aspects of Medical Therapy in Graves Disease.

Shah R and 2 others. Endocr Pract, 2025. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Management Aspects of Medical Therapy in Graves Disease. Papers, record 39701285. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39701285

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Management Aspects of Medical Therapy in Graves Disease.
PubMed
Journal
Endocr Pract
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
2.4, provisional
iCite
Revised in PubMed
2026-03-07
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Shah RRutu
2Adamson SESamantha E
3Jasim SSina

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Graves DiseaseMajor topic
Antithyroid AgentsMajor topic
Humans
Pregnancy
Female
Iodine Radioisotopes
Pregnancy Complications

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
K08 DK142012NIDDK NIH HHSUnited StatesK08DK142012PubMedNIH RePORTER
K12 DK133995NIDDK NIH HHSUnited StatesK12DK133995PubMed and NIHNIH RePORTER

Download CSV of grants

References99

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118946064Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.N Engl J Med2008https://conductscience.org/library/papers/18946064PubMed
234760672Rapid Differential Diagnosis of Thyrotoxicosis Using T3/T4 Ratio, FT3/FT4 Ratio and Color Doppler of Thyroid Gland.Indian J Endocrinol Metab2021https://conductscience.org/library/papers/34760672PubMed
319445623Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily.Thyroid2009https://conductscience.org/library/papers/19445623PubMed
4356624422022 Update on Clinical Management of Graves Disease and Thyroid Eye Disease.Endocrinol Metab Clin North Am2022https://conductscience.org/library/papers/35662442PubMed
521044113Subclinical thyrotoxicosis in an outpatient population - predictors of outcome.Clin Endocrinol (Oxf)2011https://conductscience.org/library/papers/21044113PubMed
636706788Comparison Between Thyroid Stimulating Immunoglobulin and TSH-Receptor Antibodies in the Management of Graves' Orbitopathy.Exp Clin Endocrinol Diabetes2023https://conductscience.org/library/papers/36706788PubMed
716571093
Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
Thyroid2006https://conductscience.org/library/papers/16571093PubMed
8302837352018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.Eur Thyroid J2018https://conductscience.org/library/papers/30283735PubMed
91691908Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.Arch Intern Med1990https://conductscience.org/library/papers/1691908PubMed
1032107168Graves' disease: Epidemiology, genetic and environmental risk factors and viruses.Best Pract Res Clin Endocrinol Metab2020https://conductscience.org/library/papers/32107168PubMed
1112794168Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves' disease is mediated through the insulin-like growth factor I receptor pathway.J Immunol2003https://conductscience.org/library/papers/12794168PubMed
1231772785A Case Report of Graves' Disease Induced by the Anti-Human Programmed Cell Death-1 Monoclonal Antibody Pembrolizumab in a Bladder Cancer Patient.Case Rep Endocrinol2019https://conductscience.org/library/papers/31772785PubMed
1325149085Thymic hyperplasia in patients with Graves' disease.J Endocrinol Invest2014https://conductscience.org/library/papers/25149085PubMed
1412915620Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies.J Clin Endocrinol Metab2003https://conductscience.org/library/papers/12915620PubMed
1532811342Treatment of Subclinical Hyperthyroidism in the Elderly: Comparison of Radioiodine and Long-Term Methimazole Treatment.Thyroid2021https://conductscience.org/library/papers/32811342PubMed
166467634Maternal hyperthyroidism and congenital malformation in the offspring.Clin Endocrinol (Oxf)1984https://conductscience.org/library/papers/6467634PubMed
1721591944Selenium and the course of mild Graves' orbitopathy.N Engl J Med2011https://conductscience.org/library/papers/21591944PubMed
1830320502ANNIVERSARY REVIEW: Antithyroid drug therapy: 70 years laterEur J Endocrinol2018https://conductscience.org/library/papers/30320502PubMed
1928467880Teprotumumab for Thyroid-Associated Ophthalmopathy.N Engl J Med2017https://conductscience.org/library/papers/28467880PubMed
2029771756Thyrotropin Receptor Antibodies-An Overview.Ophthalmic Plast Reconstr Surg2018https://conductscience.org/library/papers/29771756PubMed

See all 99 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42894817Genetic polymorphisms and early responses predict refractory hyperthyroidism during antithyroid drug therapy.iScience2026https://conductscience.org/library/papers/42894817PubMed
42775368Refractory Graves' Disease With Propylthiouracil-Induced Hemophagocytic Lymphohistiocytosis and Multiple Drug Allergies Treated With Total Thyroidectomy: A Case Report.Cureus2026https://conductscience.org/library/papers/42775368PubMed
42661926Cytokines and drugs targeting cytokines in Graves' disease and thyroid eye disease.Front Immunol2026https://conductscience.org/library/papers/42661926PubMed
41917239Aescin and rutin mitigate hyperthyroidism-induced multisystem dysfunction via antioxidant and anti-inflammatory mechanisms in a rat model.Sci Rep2026https://conductscience.org/library/papers/41917239PubMed
41894843Severe agranulocytosis in patient with Graves' disease on second exposure to carbimazole.Endocrinol Diabetes Metab Case Rep2026https://conductscience.org/library/papers/41894843PubMed
41657797Analysis of the impact of Graves' disease on the efficacy of initial radioactive iodine therapy in patients with differentiated thyroid cancer.Am J Cancer Res2026https://conductscience.org/library/papers/41657797PubMed
41373736Special Issue "Molecular Biology of the Thyroid Cancer and Thyroid Dysfunctions".Int J Mol Sci2025https://conductscience.org/library/papers/41373736PubMed
41021009Association between maternal thyroid dysfunction and neurodevelopmental disorders in offspring: a population-based cohort study.Eur Child Adolesc Psychiatry2026https://conductscience.org/library/papers/41021009PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39701285

GET https://conductscience.org/api/papers/v1/39701285/references?page=2